Genscript Biotech Corporation
金斯瑞生物科技股份有限公司 *
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1548)

SUPPLEMENTAL ANNOUNCEMENT

Reference is made to the voluntary announcement of GenScript Biotech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") dated 12 January 2021 (the "**Announcement**") in relation to Legend Biotech Corporation's virtual participation in the 39th Annual J.P. Morgan Healthcare Conference 2021. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

On 13 January 2021 (New York time), Legend Biotech Corporation ("**Legend Biotech**") will present company updates at the Conference (the "**Presentation**"). In the Presentation, Legend Biotech will disclose that it aims to file a Marketing Authorization Application (MAA) for ciltacabtagene autoleucel (cilta-cel) with the European Medicines Agency (EMA) in the first half of 2021 and to file a Biologics License Application (BLA) for cilta-cel in China in the second half of 2021. The Presentation also reflects the following timing targets with respect to cilta-cel: receipt of approval by the U.S. Food and Drug Administration (FDA) in United States targeted for the second half of 2021, receipt of approval by the European Medicines Agency (EMA) in the European Union targeted for 2022, and receipt of approval by the Center for Drug Evaluation (CDE) in China targeted for 2022, respectively. In addition, Legend Biotech intends to initiate its phase 1 study for LB1901 for T-cell Lymphoma in the United States in 2021.

The Presentation will also include an overview of (i) Legend Biotech's cell therapy platform, (ii) the clinical development of cilta-cel, (both (i) and (ii) have previously been disclosed by the Company), and (iii) future potential milestone payments (subject to achievement of the relevant milestone events) upon the occurrence of various milestone events pursuant to the terms and conditions of the collaboration with Janssen Biotech, Inc.

The above summary of the Presentation shall be read in conjunction with the full Presentation which is available on Legend Biotech's website at https://investors.legendbiotech.com/events/event-details/legend-biotech-participate-39th-annual-jp-morgan-healthcare-conference.

This announcement and the Presentation contain "forward-looking statements". The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, statements relating to the Group's strategies and objectives; the anticipated timing of, and ability to progress, clinical trials; the ability to make, and the timing of, regulatory submissions in the United States, Europe and Asia, including the ongoing BLA filings for cilta-cel to the U.S. FDA, the submission of a marketing authorization application for cilta-cel to the EMA, and the submission of an IND LB1901 in relapsed or refractory TCL; the ability to generate, analyze and present data from clinical trials; patient enrollment; anticipated timing regarding regulatory approvals by the FDA, EMA or CDE; and the potential benefits of Legend Biotech's product candidates. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests of additional safety and/or efficacy data or analysis of data, or government regulation generally unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to the Group's patent or other proprietary intellectual property protection, including uncertainties involved in the US litigation process; competition in general; government, industry a, an general public pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Meng Jiange
Chairman and Executive Director

Hong Kong, 13 January 2021

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*